David Katz Longeveron Inc. Transaction History

Matrix Asset Advisors Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$2.92 - $42.3 $252,288 - $3.65 Million	-86,400 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.4 - $8.3 $174,760 - $426,620	51,400 Added 146.86%	86,400 $305,000
Q2 2021 Aug 16, 2021	BUY	$5.2 - $8.13 $26,000 - $40,650	5,000 Added 16.67%	35,000 $285,000
Q1 2021 May 13, 2021	BUY	$5.66 - $8.45 $169,800 - $253,499	30,000 New	30,000 $198,000

1.18K

Ticker LGVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,925,940
Market Cap $10.7M
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...

Get notified when there are updates to the investment portfolio of Matrix Asset Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Matrix Asset Advisors Inc and David Katz with notifications on news.